Endocrine Cancer

News alerts, weekly reports and conference planners

NTRK2 fusion	Thyroid Gland Papillary Carcinoma	NTRK2 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK3 fusion	Thyroid Gland Papillary Carcinoma	NTRK3 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK1 fusion	Thyroid Gland Papillary Carcinoma	NTRK1 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week (New C4) trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1wk	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1 week - (New C4)
CCDC6‐RET fusion + TERT promotor mutation	Thyroid Gland Anaplastic Carcinoma	CCDC6‐RET fusion + TERT promotor mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: C4 – Case Studies ATA 2023 - 1 week (New C4) selpercatinib Sensitive : C4 ATA 2023 - 1wk	selpercatinib Sensitive: C4 – Case Studies ATA 2023 - 1 week selpercatinib Sensitive : C4 ATA 2023 - 1 week - (New C4)
RET C634W	Thyroid Gland Medullary Carcinoma	RET C634W	Thyroid Gland Medullary Carcinoma	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week (New D) TAS0953 / HM06 Sensitive : D Nat Cancer - 1wk	TAS0953/HM06 Sensitive: D – Preclinical Nat Cancer - 1 week TAS0953 / HM06 Sensitive : D Nat Cancer - 1 week - (New D)
TMB-H	Thyroid Gland Medullary Carcinoma	TMB-H	Thyroid Gland Medullary Carcinoma	Immunotherapy Sensitive: C4 – Case Studies Thyroid - 3 weeks (New C4) Immunotherapy Sensitive : C4 Thyroid - 3wk	Immunotherapy Sensitive: C4 – Case Studies Thyroid - 3 weeks Immunotherapy Sensitive : C4 Thyroid - 3 weeks - (New C4)
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	PLX4720 + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks (New D) PLX4720 + axitinib Sensitive : D Thyroid - 3wk	PLX4720 + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks PLX4720 + axitinib Sensitive : D Thyroid - 3 weeks - (New D)
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks (New D) dabrafenib + axitinib Sensitive : D Thyroid - 3wk	dabrafenib + axitinib Sensitive: D – Preclinical Thyroid - 3 weeks dabrafenib + axitinib Sensitive : D Thyroid - 3 weeks - (New D)
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
TMB-H	Thyroid Gland Hurthle Cell Carcinoma	TMB-H	Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2

Endocrine Cancer

Associations(404)

Associations
(404)